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Traditional methods of postoperative analgesia do not
provide adequate control of pain, in part because they
focus on treating the patient only after the pain is well
entrenched. Despite recent advances in the management
of postoperative pain, up to 60% of patients continue to
report moderate to severe pain shortly after surgery.1
Patients are ordinarily transported to the recovery room,
in considerable pain, where they receive high doses of
morphine in an attempt to bring the pain under control.
The idea behind pre-emptive analgesia is to administer
analgesics or local anaesthetics before the start of surgery
with the aim of reducing postoperative pain intensity and
postoperative analgesic requirements. The concept is not
simply that pre-emptive analgesia reduces pain during the
procedure, although that in itself is a worthwhile goal.The
hypothesis is that the transmission of noxious afferent
input from the periphery (brought about by, for example,
pre-amputation pain, incision and subsequent noxious
intraoperative events, and postoperative noxious inputs
from the amputation stump) to the spinal cord induces a
prolonged state of central neural sensitisation or
hyperexcitability that amplifies subsequent input from the
wound and leads to increased postoperative pain. By
interrupting the transmission of noxious peri-operative
inputs to the spinal cord, a pre-emptive approach is
thought to prevent the establishment of central
sensitisation and to result in reduced pain and analgesic
requirements after the analgesic effects of the (pre-
emptive) agents have worn off.
The need for well-controlled trials to find out whether
regional anaesthesia given before, during, or after surgery
prevents long-term phantom-limb pain was discussed in
these columns only earlier this year.2 We know that more
than 70% of amputees report phantom-limb pain years
after amputation,2 but we do not know the factors
responsible for the transition of acute postoperative pain
to long-term pain. In today’s Lancet Lone Nikolajsen and
colleagues report the results of a randomised trial
evaluating the long-term effects on phantom limb and
stump pain of continuous epidural morphine and
bupivacaine administered 18 hours before, during, and for
about a week after lower-limb amputation. The control
group received epidural saline before and throughout the
surgical procedure, followed by epidural morphine and
bupivacaine postoperatively. There were no significant
differences between the groups in pain incidence, pain
intensity, or opioid consumption at any time up to 12
months after surgery. This work is by far the most
carefully controlled study done to date. What is the future
for preventive or pre-emptive epidural anaesthesia for
amputation? What further studies should be done?
The accompanying figure shows the eight possible
treatment combinations for timing of regional anaesthesia
for amputations. Also depicted are the positive and
negative trials conducted so far, along with their
treatment comparisons. On the basis of existing data, the
study design with the most potential for reducing long-
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term phantom limb pain would be a well-controlled
replication of the studies by Jahangiri et al3 and Schug et
al4 comparing pre-operative, intra-operative, and post-
operative epidural treatment with a placebo or sham
epidural control. Logistical and ethical considerations,
however, may make such a study difficult to implement in
a double-blind, placebo-controlled fashion.
The ability to demonstrate a pre-emptive analgesic
effect depends on the interaction of multiple factors,
including the extent and nature of damaged tissue,
duration of surgery, agents used pre-emptively, their route
and timing of administration and their duration of action,
extent of afferent blockade, ability of other agents given
during surgery to pre-empt postoperative pain, and the
time course of central sensitisation. Further research of
the calibre of the study by Nikolajsen and colleagues is
called for to take into account these factors before an
informed conclusion can be reached on the basis of
empirical evidence.
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Preterm labour and delivery continue to occupy the
obstetrical research community because of the public
health problem they continue to generate. Existing
therapies for preterm labour at best delay delivery for 
48 hours, during which time glucocorticoids can be given
to enhance fetal lung maturity, and so reduce the
likelihood or severity of respiratory distress syndrome,
intraventricular haemorrhage, necrotising enterocolitis,
neonatal death, and length of neonatal hospital stay.
Nifedipine is being evaluated as a potentially safer, more
effective treatment for preterm labour than the -
sympathomimetic agents routinely in use.1–4 The latest of
these evaluations is the multicentre randomised clinical
trial by D N Papatsonis and colleagues,5 of nifedipine
versus ritodrine, a commonly used -adrenergic agent,
and it is first to show significant postponement of delivery
with oral nifedipine treatment, compared with
intravenous or oral ritodrine.
The study was designed to assess the efficacy in
delaying labour, perinatal outcomes, and maternal side-
effects. Nifedipine was given orally and ritodrine
intravenously followed by oral administration. The two
treatment arms were stratified for gestational-age and state
of membranes (intact or ruptured). Indomethacin was
used in both treatment arms as a second-line agent when
primary therapy at maximum dose did not arrest
contractions. The doses of nifedipine used were higher
than earlier work and were based on a retrospective safety
and efficacy study by the same group of investigators.1
Apart from being more effective than ritodrine in
preventing labour, even at these higher doses nifedipine
produced significantly fewer maternal side-effects, as well
as admissions to the neonatal intensive-care unit.
Interestingly, for patients with ruptured membranes, there
were no differences in ritodrine versus nifedipine
treatment. This finding points to a difference in
pathogenesis between preterm labour due to premature
rupture of membranes and preterm labour with intact
membranes. In the latter group, nifedipine significantly
decreased the percentage of deliveries before 34 weeks’
gestation. Moreover, the authors report compelling
evidence that nifedipine is better tolerated than ritodrine.
Although these promising results might encourage
clinicians to adopt nifedipine as a standard treatment for
patients with active preterm labour, it remains to be seen
whether nifedipine is categorically different from ritodrine,
terbutaline, or magnesium sulphate in its ability to prolong
gestation until term. Indeed, this study had sufficient
power only to detect the ability of the drug to outperform
ritodrine in delaying delivery to the end of the first week.
Oxytocin antagonists, such as atosiban, have recently
entered the tocolysis scene, but preliminary results place
them in the same relatively ineffective category.6
There are also limitations imposed by the study design.
It did not allow for crossover of therapeutic regimens, and
in fact 12 patients in the ritodrine group switched to
nifedipine because of severe side-effects were excluded
from the analysis, whereas the practical realities of patient
care require that trials be analysed by intent to treat. In
addition, results may have been influenced by the
subsequent use of indomethacin, which was administered
to a subset of patients in both groups. And although the
authors report no difference among participating hospitals
in the delay of delivery in the ritodrine-treatment group,
one hospital did not administer oral ritodrine after
cessation of intravenous therapy. There is also the
possibility of systematic investigator bias, because
clinicians ranked the severity of side-effects and decided
when they were severe enough to warrant a change in
treatment.
Lastly, should we be comfortable with the safety of the
drug? Like its -adrenergic and magnesium sulphate
alternatives, it is a non-specific agent, acting as a smooth-
muscle relaxant throughout the body. However, unlike its
alternatives, it has not been associated with increased risk
of pulmonary oedema and myocardial ischaemia.
Concerns remain over its potential adverse effects on
uteroplacental blood flow,7 although some investigators
have not confirmed this fear.5 The authors have reported
on the lack of either maternal or neonatal side-effects with
relatively high doses of nifedipine,1 but this aspect of the
drug’s use should be considered still unresolved.
Since none of the existing treatments truly arrest the
process for more than a few days, and on the assumption
that they are similar in severity and frequency of side-
effects, the most important outcome measure can be
argued to be admission rates to the neonmatal intensive-
care unit. As a proxy for serious morbidity, as well as for
cost, admissions to the intensive-care unit represent a
straightforward measure of the value of a tocolytic agent.
In this study, the nifedipine-treated group had significantly
fewer admissions than did the ritodrine-treated group.
In view of the promising results of this study, coupled
with the relative ineffectiveness of alternative treatments,
our next step should be the design and execution of a
randomised, double-blind, placebo-controlled trial of
nifedipine. To allow time to give  glucocorticoids and for
overall evaluation of the fetus, both treatment and control
groups would receive tocolyctic therapy for at least 48
hours. In this manner, we can collect definitive data on the
efficacy and acceptability profile of the product. If the
drug’s safety profile remains encouraging on further
evaluation, it may well represent the best tocolytic
alternative currently available.
????????? ????????
????? ??????????????????????????????????? ??????? ?????????????????????
??? ?????????????? ??????????????????
1 van Dijk KG, Dekker GA, van Geijn HP. Ritodrine and nifedipine as
tocolytic agents: a preliminary comparison. J Perinat Med 1995; 23:
409–15.
2 Kupfermine M, Lessing JB,Yaron Y, Peyser MR. Nifedipine versus
ritodrine for suppression of preterm labour. Br J Obstet Gynaecol 1993;
100: 1090–94.
3 Bracero LA, Leikin E, Kirshenbaum N,Tejani N. Comparison of
nifedipine and ritodrine for the treatment of preterm labor. Am J
Perinatol 1991; 8: 365–69.
4 Meyer WR, Randall HW, Graves WL. Nifedipine versus ritodrine for
suppressing preterm labor. J Reprod Med 1990; 35: 649–53.
5 Papatsonis DN,Van Geijn HP, Ader HJ, Lange FM, Bleker OP, Dekker
GA. Nifedipine and ritodrine in the management of preterm labor: a
randomized multicenter trial. Obstet Gynecol 1997; 90: 230–34.
postoperative opioid requirements and phantom limb pain following
amputation. J Rehab Res Devt 1994; 31: 179-87.
8 Pinzur MS, Garla PGN, Pluth T,Vrbos L. Continuous postoperative
infusion of a regional anesthetic after an amputation of the lower
extremity: A randomized clinical trial. J Bone Jt Surg 1996; 78-A:
1501-05.
